SCHEMBL13662811

SCHEMBL13662811

COC(=O)C1CCCN([C@@H](C)c2ccc(F)cc2)C1=O

nearest known ligand 0.43

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.43
SLC6A3 Q01959 9/20 0.39
SLC6A4 P31645 6/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8030829 0.87 HSD11B1 (0.44) HSD11B1
SCHEMBL4296589 0.86 HSD11B1 (0.46) HSD11B1
SCHEMBL28775897 0.86 HSD11B1 (0.46) HSD11B1
SCHEMBL8038060 0.79 HSD11B1 (0.51) HSD11B1
SCHEMBL27740269 0.78 HSD11B1 (0.43) HSD11B1
SCHEMBL4294143 0.77 HSD11B1 (0.45) HSD11B1
SCHEMBL4304050 0.77 HSD11B1 (0.45) HSD11B1
SCHEMBL4100291 0.77 HSD11B1 (0.45) HSD11B1
SCHEMBL4298912 0.77 HSD11B1 (0.45) HSD11B1
SCHEMBL8030808 0.76 HSD11B1 (0.46) HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270623-A1 PROCESS FOR PRODUCTION OF CINNAMIDE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-10-29 US disclosed
US-20090270623-A1 PROCESS FOR PRODUCTION OF CINNAMIDE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270623-A1 PROCESS FOR PRODUCTION OF CINNAMIDE DERIVATIVE CBR1, H1-0, CBR3 HSD11B1 495/4885SLC6A3 4656/4885SLC6A4 4332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.